Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The MYC promoter G-quadruplex is a non-canonical, four-stranded DNA structure formed within the nuclease hypersensitive element III1 (NHE III1) of the MYC (c-MYC) oncogene promoter [NIH, 2015; ResearchGate, 2024]. This structure consists of stacked guanine tetrads stabilized by monovalent cations and acts as a critical molecular switch for transcriptional regulation [NIH, 2021; ResearchGate, 2024]. Under normal physiological conditions, the formation of the G-quadruplex serves as a transcriptional silencer by physically obstructing RNA polymerase and displacing activating transcription factors like Sp1 [NIH, 2015; MDPI, 2023]. In many cancers, MYC is overexpressed due to the resolution of this structure by proteins such as NM23-H2, driving uncontrolled cell proliferation and survival [NIH, 2015; NIH, 2023]. Therapeutic strategies focus on using small-molecule ligands to stabilize the G-quadruplex, thereby repressing MYC transcription and inducing apoptosis in cancer cells [MDPI, 2023; NIH, 2023]. However, achieving high selectivity for the MYC G-quadruplex over thousands of other G-quadruplexes in the genome remains a significant challenge in drug development [MDPI, 2023; NIH, 2024].
Stabilization of the G-quadruplex structure within the nuclease hypersensitive element III1 (NHE III1) of the MYC promoter, which physically blocks the transcriptional machinery and displaces activating transcription factors, leading to the downregulation of MYC oncogene expression [NIH, 2015; MDPI, 2023].
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MYC promoter G-quadruplex (MYC G4).